Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR9114 intranasal influenza A human challenge study
2023-505020-57-00Phase 2Completed
- Sponsor
- Leyden Labs
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CR9114 in Influenza A infection (3 arms), sponsored by Leyden Labs. Primary endpoints: Incidence of MMIDa and Treatment-emergent adverse events and serious adverse events. Started Jul 2023; status: completed.
02
Drugs
CR9114
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2023-505020-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505020-57-00.